Ahead of the Dec. 5 presentation of aducanumab data at the Clinical Trials on Alzheimer's Disease annual congress, Baird put forward a bearish thesis on why the pipeline asset is unlikely to receive FDA approval.
Brian Skorney downgraded Biogen from Neutral to Underperform with a $250 price target.
Biogen's CTAD presentation could serve as a meaningful negative catalyst for Biogen, with the hype around aducanumab descending into broader critique of the full data set and the company's decision to file based on it, Skorney said in a Monday note. (See his track record here.)
When the clinical benefit as measured from the EMERGE study is characterized, it is going to disappoint, the analyst said.
The numerical benefit is around 0.4 points compared to 0.5 points for Eisai Co., Ltd's (OTC: ESALY) marketed drug Aricept and 0.34 points for Eli Lilly And Co's (NYSE: LLY) pipeline asset solaneuzumab.
The safety disclosure for aducanumab is at the bare minimum, he said.
Aducanumab falls far short of a compelling argument for approval, Skorney said.
"The bottom line is, the FDA standard of approval is substantial evidence of efficacy and the cumulative data for aducanumab falls really far short of this standard to anyone but the most ardent GOOP subscribers."
Biogen shares were down 2.58% at $292.06 at the time of publication Monday.
Benzinga's Top Upgrades, Downgrades For December 2, 2019
Attention Biotech Investors: Mark Your Calendar For These December PDUFA Dates
Latest Ratings for BIIB
|Nov 2019||Initiates Coverage On||Buy|
View More Analyst Ratings for BIIB
View the Latest Analyst Ratings
See more from Benzinga
- The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More
- Biotech Stock On The Radar: Alkermes At A Crossroads
- AstraZeneca Named The Most Innovative Global Pharma Company
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.